CL2017001073A1 - 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos - Google Patents

2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos

Info

Publication number
CL2017001073A1
CL2017001073A1 CL2017001073A CL2017001073A CL2017001073A1 CL 2017001073 A1 CL2017001073 A1 CL 2017001073A1 CL 2017001073 A CL2017001073 A CL 2017001073A CL 2017001073 A CL2017001073 A CL 2017001073A CL 2017001073 A1 CL2017001073 A1 CL 2017001073A1
Authority
CL
Chile
Prior art keywords
quinolia
diamino
substituted
anticancer agents
new anticancer
Prior art date
Application number
CL2017001073A
Other languages
English (en)
Inventor
Clarisse Dubray
Gregory Nicolas
Philippe Halfon
Firas Bassissi
Antoine Beret
Sonia Brun
Jerome Courcambeck
Original Assignee
Genoscience Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma filed Critical Genoscience Pharma
Publication of CL2017001073A1 publication Critical patent/CL2017001073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

<p>LA PRESENTE INVENCIÓN SE RELACIONA CON DERIVADOS NOVEDOSOS DE 2-PRIMARIA AMINO-4-SECUNDARIA AMINO-QUINOLINA, SU FABRICACIÓN, COMPOSICIONES FARMACÉUTICAS QUE LAS COMPRENDEN Y SU USO COMO MEDICAMENTOS. LOS COMPUESTOS ACTIVOS DE LA PRESENTE INVENCIÓN SON ÚTILES PARA EL TRATAMIENTO Y PREVENCIÓN DE ENFERMEDADES NEOPLÁSTICAS Y NO NEOPLÁSTICAS PROLIFERATIVAS.</p>
CL2017001073A 2014-10-31 2017-04-28 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos CL2017001073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31

Publications (1)

Publication Number Publication Date
CL2017001073A1 true CL2017001073A1 (es) 2018-01-12

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001073A CL2017001073A1 (es) 2014-10-31 2017-04-28 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos

Country Status (34)

Country Link
US (1) US10722505B2 (es)
EP (1) EP3212629B1 (es)
JP (1) JP6588546B2 (es)
KR (1) KR102548547B1 (es)
CN (1) CN107148416B (es)
AU (1) AU2015338844B2 (es)
CA (1) CA2965262C (es)
CL (1) CL2017001073A1 (es)
CO (1) CO2017007325A2 (es)
CR (1) CR20170177A (es)
CY (1) CY1121326T1 (es)
DK (1) DK3212629T3 (es)
DO (1) DOP2017000107A (es)
EA (1) EA037119B1 (es)
EC (1) ECSP17026748A (es)
ES (1) ES2707125T3 (es)
GE (1) GEP20207108B (es)
HR (1) HRP20190107T1 (es)
IL (1) IL251775B (es)
LT (1) LT3212629T (es)
MA (1) MA40875B1 (es)
MY (1) MY193740A (es)
NI (1) NI201700052A (es)
PE (1) PE20191142A1 (es)
PH (1) PH12017500810A1 (es)
PL (1) PL3212629T3 (es)
PT (1) PT3212629T (es)
RS (1) RS58328B1 (es)
SG (1) SG11201703479SA (es)
SI (1) SI3212629T1 (es)
TN (1) TN2017000168A1 (es)
TR (1) TR201900148T4 (es)
UA (1) UA122062C2 (es)
WO (1) WO2016067112A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
EP1601357A4 (en) * 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
SG10201705662WA (en) * 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
BR112015023948A2 (pt) * 2013-03-18 2017-07-18 Genoscience Pharma composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer

Also Published As

Publication number Publication date
CA2965262A1 (en) 2016-05-06
RS58328B1 (sr) 2019-03-29
DK3212629T3 (en) 2019-02-18
ECSP17026748A (es) 2018-03-31
TN2017000168A1 (en) 2018-10-19
ES2707125T3 (es) 2019-04-02
NI201700052A (es) 2017-09-11
CA2965262C (en) 2023-03-14
LT3212629T (lt) 2019-01-10
CN107148416B (zh) 2020-05-05
PL3212629T3 (pl) 2019-05-31
US10722505B2 (en) 2020-07-28
EP3212629A1 (en) 2017-09-06
MY193740A (en) 2022-10-27
EA201790949A1 (ru) 2018-02-28
EA037119B1 (ru) 2021-02-09
CR20170177A (es) 2017-09-19
SG11201703479SA (en) 2017-05-30
BR112017018637A2 (pt) 2022-07-05
PH12017500810A1 (en) 2017-10-02
PE20191142A1 (es) 2019-09-02
MA40875A (fr) 2017-09-06
GEP20207108B (en) 2020-05-11
AU2015338844B2 (en) 2019-09-19
KR102548547B1 (ko) 2023-06-27
TR201900148T4 (tr) 2019-02-21
UA122062C2 (uk) 2020-09-10
AU2015338844A1 (en) 2017-05-04
PT3212629T (pt) 2019-02-04
CN107148416A (zh) 2017-09-08
WO2016067112A1 (en) 2016-05-06
EP3212629B1 (en) 2018-10-24
CO2017007325A2 (es) 2017-10-20
DOP2017000107A (es) 2017-09-15
IL251775B (en) 2020-07-30
SI3212629T1 (sl) 2019-02-28
NZ731345A (en) 2023-09-29
JP2017538673A (ja) 2017-12-28
GEAP202014494A (en) 2020-01-27
MA40875B1 (fr) 2019-01-31
KR20170077160A (ko) 2017-07-05
JP6588546B2 (ja) 2019-10-09
US20190314359A1 (en) 2019-10-17
IL251775A0 (en) 2017-06-29
HRP20190107T1 (hr) 2019-03-08
CY1121326T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
DOP2015000274A (es) Compuestos químicos
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
ECSP16074478A (es) Compuestos novedosos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
ECSP17069696A (es) Compuestos novedosos
CR20160133A (es) Derivados de fenilalanina sustituidos
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CU20180044A7 (es) Derivados novedosos de diamino piridina
ECSP18056196A (es) Derivados de indano